In recent years, the use of EGFR-tyrosine kinase inhibitors such as erlotinib and osimertinib has markedly prolonged survival for patients with MM from EGFR mutation-positive NSCLC [4,5]. Here, EGFR is linked to non-small cell lung carcinoma.